Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sacks

Showing results (21-30 of 626) with videos related to

Pageof 63
Sort By:
Connecticut Medicine|July 1, 1976
Checks and balances stymie title XX confidentiality threatsH S Sacks
Annals of Internal Medicine|April 21, 2020
Adding oseltamivir to usual primary care reduced recovery time in influenza-like illnessHenry S Sacks
Annals of Internal Medicine|January 20, 2016
ACP Journal Club. Preexposure tenofovir-emtricitabine reduced HIV infection in men who have unprotected anal sex with menHenry S Sacks
The Online Journal of Current Clinical Trials|October 7, 1993
Treatment of early or asymptomatic HIV infection. Where are we and where do we go from here?H S Sacks
Conference Proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference|October 20, 2007
Biomechanics of engineered heart valve tissuesMichael S Sacks
Journal of Applied Physiology (Bethesda, Md. : 1985)|October 25, 2008
Weight loss in obesity reduces epicardial fat thickness; so what?Harold S Sacks
Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition|October 11, 2005
Enhancing the response to parenteral nutrition in critical careGordon S Sacks
Annals of Internal Medicine|October 6, 2025
In primary CDI, fecal microbiota transplantation was noninferior to vancomycin for clinical cure at 14 d without recurrence at 60 dHenry S Sacks,
Annals of Internal Medicine|February 22, 2012
ACP Journal Club. Adding procalcitonin-guided therapy to standard care did not reduce mortality in critically ill patientsHenry S Sacks
Annals of Internal Medicine|July 5, 2021
The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 dHenry S Sacks
Pageof 63

Showing results (21-30 of 626) with videos related to

Sort By:
Pageof 63
Connecticut Medicine|July 1, 1976
Checks and balances stymie title XX confidentiality threatsH S Sacks
Annals of Internal Medicine|April 21, 2020
Adding oseltamivir to usual primary care reduced recovery time in influenza-like illnessHenry S Sacks
Annals of Internal Medicine|January 20, 2016
ACP Journal Club. Preexposure tenofovir-emtricitabine reduced HIV infection in men who have unprotected anal sex with menHenry S Sacks
The Online Journal of Current Clinical Trials|October 7, 1993
Treatment of early or asymptomatic HIV infection. Where are we and where do we go from here?H S Sacks
Conference Proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference|October 20, 2007
Biomechanics of engineered heart valve tissuesMichael S Sacks
Journal of Applied Physiology (Bethesda, Md. : 1985)|October 25, 2008
Weight loss in obesity reduces epicardial fat thickness; so what?Harold S Sacks
Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition|October 11, 2005
Enhancing the response to parenteral nutrition in critical careGordon S Sacks
Annals of Internal Medicine|October 6, 2025
In primary CDI, fecal microbiota transplantation was noninferior to vancomycin for clinical cure at 14 d without recurrence at 60 dHenry S Sacks,
Annals of Internal Medicine|February 22, 2012
ACP Journal Club. Adding procalcitonin-guided therapy to standard care did not reduce mortality in critically ill patientsHenry S Sacks
Annals of Internal Medicine|July 5, 2021
The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 dHenry S Sacks
Pageof 63